Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level

In view of the present controversy related to the potential beneficial effects of clinical dehydroepiandrosterone (DHEA) treatments, and considering our own previous results that reveal an influence of this steroid in pituitary hyperplasia development in vivo in rats, we decided to evaluate the role...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado: 2005
Materias:
rat
Acceso en línea:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00220795_v185_n1_p165_Suarez
http://hdl.handle.net/20.500.12110/paper_00220795_v185_n1_p165_Suarez
Aporte de:
id paper:paper_00220795_v185_n1_p165_Suarez
record_format dspace
spelling paper:paper_00220795_v185_n1_p165_Suarez2023-06-08T14:45:26Z Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level androstenediol angiotensin calcium ion cyclic AMP dopamine drug metabolite growth hormone growth hormone releasing factor prasterone prolactin somatostatin adenohypophysis animal cell article calcium mobilization concentration response controlled study cytokine production female growth hormone release hormonal regulation hormone inhibition hormone response hypophysis cell hypothalamus in vitro study nonhuman priority journal prolactin release rat Angiotensin II Animals Calcium Cell Culture Techniques Cyclic AMP Dehydroepiandrosterone Female Glucocorticoids Growth Hormone Growth Hormone-Releasing Hormone Pituitary Gland, Anterior Prolactin Rats Rats, Sprague-Dawley Somatostatin Stimulation, Chemical In view of the present controversy related to the potential beneficial effects of clinical dehydroepiandrosterone (DHEA) treatments, and considering our own previous results that reveal an influence of this steroid in pituitary hyperplasia development in vivo in rats, we decided to evaluate the role of DHEA in prolactin and GH secretion, as well as in second messengers involved, in cultured rat anterior pituitary cells. DHEA (1 × 10-5 to 1 × 10-7 M) did not modify basal GH or prolactin release, and a prolactin inhibitory effect was observed only for androstenediol, a metabolite of DHEA. DHEA partially prevented dopamine (1 × 10-6 M)-induced prolactin inhibition and facilitated the prolactin-releasing effect of 10-8 M Ang II, without modifying the resulting Ca2+i mobilization. Furthermore, DHEA potentiated the GH release and cAMP production induced by 1 × 10-8 M GHRH. Finally, DHEA partially reversed the inhibitory effect of 1 × 10-8 M somatostatin on GH, but not prolactin, release. We conclude that DHEA in vitro, directly or indirectly through conversion into metabolites, is able to modulate the hormonal response of the pituitary to hypothalamic regulators. It can enhance pituitary prolactin release and induce GH secretion. These effects could help explain some of the side effects observed in prolonged DHEA treatments in vivo and should be taken into account when considering its use in human clinical trials. © 2005 Society for Endocrinology. 2005 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00220795_v185_n1_p165_Suarez http://hdl.handle.net/20.500.12110/paper_00220795_v185_n1_p165_Suarez
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic androstenediol
angiotensin
calcium ion
cyclic AMP
dopamine
drug metabolite
growth hormone
growth hormone releasing factor
prasterone
prolactin
somatostatin
adenohypophysis
animal cell
article
calcium mobilization
concentration response
controlled study
cytokine production
female
growth hormone release
hormonal regulation
hormone inhibition
hormone response
hypophysis cell
hypothalamus
in vitro study
nonhuman
priority journal
prolactin release
rat
Angiotensin II
Animals
Calcium
Cell Culture Techniques
Cyclic AMP
Dehydroepiandrosterone
Female
Glucocorticoids
Growth Hormone
Growth Hormone-Releasing Hormone
Pituitary Gland, Anterior
Prolactin
Rats
Rats, Sprague-Dawley
Somatostatin
Stimulation, Chemical
spellingShingle androstenediol
angiotensin
calcium ion
cyclic AMP
dopamine
drug metabolite
growth hormone
growth hormone releasing factor
prasterone
prolactin
somatostatin
adenohypophysis
animal cell
article
calcium mobilization
concentration response
controlled study
cytokine production
female
growth hormone release
hormonal regulation
hormone inhibition
hormone response
hypophysis cell
hypothalamus
in vitro study
nonhuman
priority journal
prolactin release
rat
Angiotensin II
Animals
Calcium
Cell Culture Techniques
Cyclic AMP
Dehydroepiandrosterone
Female
Glucocorticoids
Growth Hormone
Growth Hormone-Releasing Hormone
Pituitary Gland, Anterior
Prolactin
Rats
Rats, Sprague-Dawley
Somatostatin
Stimulation, Chemical
Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level
topic_facet androstenediol
angiotensin
calcium ion
cyclic AMP
dopamine
drug metabolite
growth hormone
growth hormone releasing factor
prasterone
prolactin
somatostatin
adenohypophysis
animal cell
article
calcium mobilization
concentration response
controlled study
cytokine production
female
growth hormone release
hormonal regulation
hormone inhibition
hormone response
hypophysis cell
hypothalamus
in vitro study
nonhuman
priority journal
prolactin release
rat
Angiotensin II
Animals
Calcium
Cell Culture Techniques
Cyclic AMP
Dehydroepiandrosterone
Female
Glucocorticoids
Growth Hormone
Growth Hormone-Releasing Hormone
Pituitary Gland, Anterior
Prolactin
Rats
Rats, Sprague-Dawley
Somatostatin
Stimulation, Chemical
description In view of the present controversy related to the potential beneficial effects of clinical dehydroepiandrosterone (DHEA) treatments, and considering our own previous results that reveal an influence of this steroid in pituitary hyperplasia development in vivo in rats, we decided to evaluate the role of DHEA in prolactin and GH secretion, as well as in second messengers involved, in cultured rat anterior pituitary cells. DHEA (1 × 10-5 to 1 × 10-7 M) did not modify basal GH or prolactin release, and a prolactin inhibitory effect was observed only for androstenediol, a metabolite of DHEA. DHEA partially prevented dopamine (1 × 10-6 M)-induced prolactin inhibition and facilitated the prolactin-releasing effect of 10-8 M Ang II, without modifying the resulting Ca2+i mobilization. Furthermore, DHEA potentiated the GH release and cAMP production induced by 1 × 10-8 M GHRH. Finally, DHEA partially reversed the inhibitory effect of 1 × 10-8 M somatostatin on GH, but not prolactin, release. We conclude that DHEA in vitro, directly or indirectly through conversion into metabolites, is able to modulate the hormonal response of the pituitary to hypothalamic regulators. It can enhance pituitary prolactin release and induce GH secretion. These effects could help explain some of the side effects observed in prolonged DHEA treatments in vivo and should be taken into account when considering its use in human clinical trials. © 2005 Society for Endocrinology.
title Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level
title_short Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level
title_full Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level
title_fullStr Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level
title_full_unstemmed Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level
title_sort dehydroepiandrosterone (dhea) modulates ghrh, somatostatin and angiotensin ii action at the pituitary level
publishDate 2005
url https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00220795_v185_n1_p165_Suarez
http://hdl.handle.net/20.500.12110/paper_00220795_v185_n1_p165_Suarez
_version_ 1768546570703208448